SwanBio Therapeutics, a gene therapy company, has named Steven Zelenkofske, DO, MS as its new chief medical officer, it was reported on Monday.
Dr Zelenkofske has over 20 years of experience. Prior to joining SwanBio Therapeutics, he served as the CMO at Achillion Pharmaceuticals and at UniQure. He has held leadership positions at Regado Biosciences, Astra-Zeneca, Sanofi-Aventis, Boston Scientific and Novartis. His work includes various therapeutic areas including neurology, immunology, haematology, cardiovascular, metabolic diseases, diabetes, and nephrology.
Tom Anderson, CEO and director of SwanBio Therapeutics, said, 'We are thrilled to add Steven's expertise to our leadership team. His background complements the extensive talent and experience of our existing management team and will help support our goal of developing gene therapies in neurological diseases that deliver real benefit to patients and their families.'
FDA Grants Priority Review to Merck's New Drug Application for Vericiguat
US FDA committee votes to recommend approval of Mallinckrodt's Terlipressin
60 Degrees Pharmaceuticals Touts Positive Results of Cell Culture Testing of Arakoda for COVID-19
Moderna, ROVI Team On OUS Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine Candidate
KKR to purchase controlling stake in J.B. Chemicals & Pharmaceuticals of India
PolyPid begins first phase three clinical trial of D-PLEX100
Moderna and Catalent Team for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine Candidate